JP2006117697A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2006117697A5 JP2006117697A5 JP2006002633A JP2006002633A JP2006117697A5 JP 2006117697 A5 JP2006117697 A5 JP 2006117697A5 JP 2006002633 A JP2006002633 A JP 2006002633A JP 2006002633 A JP2006002633 A JP 2006002633A JP 2006117697 A5 JP2006117697 A5 JP 2006117697A5
- Authority
- JP
- Japan
- Prior art keywords
- leu
- peptide
- amino acids
- peptide according
- hydrophobic amino
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108090000765 processed proteins & peptides Proteins 0.000 claims 23
- 150000001413 amino acids Chemical class 0.000 claims 17
- 230000002209 hydrophobic effect Effects 0.000 claims 12
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 5
- 208000035475 disorder Diseases 0.000 claims 5
- 230000001225 therapeutic effect Effects 0.000 claims 4
- 210000001744 T-lymphocyte Anatomy 0.000 claims 3
- 206010001889 Alveolitis Diseases 0.000 claims 2
- 208000008439 Biliary Liver Cirrhosis Diseases 0.000 claims 2
- 208000033222 Biliary cirrhosis primary Diseases 0.000 claims 2
- 206010008909 Chronic Hepatitis Diseases 0.000 claims 2
- 208000011231 Crohn disease Diseases 0.000 claims 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims 2
- 208000001204 Hashimoto Disease Diseases 0.000 claims 2
- 208000030836 Hashimoto thyroiditis Diseases 0.000 claims 2
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 2
- 201000002481 Myositis Diseases 0.000 claims 2
- 201000011152 Pemphigus Diseases 0.000 claims 2
- 208000031845 Pernicious anaemia Diseases 0.000 claims 2
- 208000012654 Primary biliary cholangitis Diseases 0.000 claims 2
- 201000004681 Psoriasis Diseases 0.000 claims 2
- 201000002661 Spondylitis Diseases 0.000 claims 2
- 230000000172 allergic effect Effects 0.000 claims 2
- 208000010668 atopic eczema Diseases 0.000 claims 2
- 230000001363 autoimmune Effects 0.000 claims 2
- 206010012601 diabetes mellitus Diseases 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 2
- 201000001155 extrinsic allergic alveolitis Diseases 0.000 claims 2
- 208000006454 hepatitis Diseases 0.000 claims 2
- 208000022098 hypersensitivity pneumonitis Diseases 0.000 claims 2
- 150000002632 lipids Chemical class 0.000 claims 2
- 230000001404 mediated effect Effects 0.000 claims 2
- 201000006417 multiple sclerosis Diseases 0.000 claims 2
- 201000001976 pemphigus vulgaris Diseases 0.000 claims 2
- 208000008494 pericarditis Diseases 0.000 claims 2
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 2
- 208000011580 syndromic disease Diseases 0.000 claims 2
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims 2
- 239000004471 Glycine Substances 0.000 claims 1
- 210000004027 cell Anatomy 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 102000004196 processed proteins & peptides Human genes 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AUPN0590A AUPN059095A0 (en) | 1995-01-16 | 1995-01-16 | Novel lipopeptide |
| AUPN0589A AUPN058995A0 (en) | 1995-01-16 | 1995-01-16 | Novel peptide |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2005034053A Division JP2005145985A (ja) | 1995-01-16 | 2005-02-10 | 新規ペプチド |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2006117697A JP2006117697A (ja) | 2006-05-11 |
| JP2006117697A5 true JP2006117697A5 (enExample) | 2006-11-09 |
| JP4522367B2 JP4522367B2 (ja) | 2010-08-11 |
Family
ID=25644844
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP52191796A Expired - Fee Related JP3665342B2 (ja) | 1995-01-16 | 1996-01-16 | 新規ペプチド |
| JP2005034053A Pending JP2005145985A (ja) | 1995-01-16 | 2005-02-10 | 新規ペプチド |
| JP2006002633A Expired - Fee Related JP4522367B2 (ja) | 1995-01-16 | 2006-01-10 | 新規ペプチド |
Family Applications Before (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP52191796A Expired - Fee Related JP3665342B2 (ja) | 1995-01-16 | 1996-01-16 | 新規ペプチド |
| JP2005034053A Pending JP2005145985A (ja) | 1995-01-16 | 2005-02-10 | 新規ペプチド |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US6057294A (enExample) |
| EP (1) | EP0804469B1 (enExample) |
| JP (3) | JP3665342B2 (enExample) |
| AU (1) | AU694602B2 (enExample) |
| CA (1) | CA2210812C (enExample) |
| DE (1) | DE69617396T2 (enExample) |
| ES (1) | ES2168456T3 (enExample) |
| WO (1) | WO1996022306A1 (enExample) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE69617396T2 (de) * | 1995-01-16 | 2002-09-05 | Northern Sydney Area Health Service, St. Leonards | T-Zellen beeinflussende Peptide |
| WO1997035881A2 (en) * | 1996-03-27 | 1997-10-02 | Ng Gordon Y K | Receptor and transporter antagonists |
| CA2257973C (en) | 1996-06-11 | 2010-02-02 | Northern Sydney Area Health Services | T cell antigen receptor peptides |
| US20050070478A1 (en) * | 1996-06-11 | 2005-03-31 | Northern Sydney Area Health Services | T cell antigen receptor peptides |
| BR9808529B1 (pt) | 1997-04-11 | 2010-10-05 | oligopeptìdeo. | |
| US6696545B1 (en) | 1997-04-11 | 2004-02-24 | Sangstat Medical Corporation | Cytomodulating lipophilic peptides for modulating immune system activity and inhibiting inflammation |
| JP2003534287A (ja) * | 2000-05-19 | 2003-11-18 | ユニバーシティ・オブ・メリーランド， ボルティモア | 糖尿病発症を予防または遅延させるためのゾヌリンのペプチドアンタゴニストの使用方法 |
| US7094413B2 (en) | 2002-01-24 | 2006-08-22 | Sangstat Medical Corporation | Combined therapy for treatment of HIV infection |
| CA2565886A1 (en) * | 2004-05-27 | 2005-12-08 | Gropep Limited | Treatment of inflammatory airway disease |
| WO2007034490A2 (en) * | 2005-09-22 | 2007-03-29 | Yeda Research And Development Co. Ltd., At The Weizmann Institute Of Science | Diastereomeric peptides for modulating t cell immunity |
| EP1870420A1 (en) * | 2006-06-23 | 2007-12-26 | Max-Delbrück-Centrum Für Molekulare Medizin | Peptides regulating the surface expression of the T cell receptor |
| US20120077732A1 (en) * | 2008-11-24 | 2012-03-29 | Sydney West Area Health Service | Cyclic peptides and uses thereof |
| US10138276B2 (en) | 2009-09-30 | 2018-11-27 | Signablok, Inc. | Inhibition of TCR signaling with peptide variants |
| WO2011047097A2 (en) | 2009-10-13 | 2011-04-21 | Sigalov Alexander B | Inhibition of trem receptor signaling with peptide variants |
| AU2018243571B2 (en) | 2017-03-31 | 2024-03-07 | The Board Of Trustees Of The Leland Standford Junior University | Methods of treating T cell exhaustion by inhibiting or modulating T cell receptor signaling |
| CA3109702A1 (en) | 2018-08-13 | 2020-02-20 | Signablok, Inc. | Peptides and compositions for targeted treatment and imaging |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5888512A (en) * | 1987-01-30 | 1999-03-30 | Board Of Trustees Of The Leland Stanford Junior University | Lymphocyte activity regulation by HLA peptides |
| JPH04503073A (ja) * | 1989-01-31 | 1992-06-04 | アボツト・ラボラトリーズ | アナフィラトキシン受容体リガンド |
| US5223485A (en) * | 1989-01-31 | 1993-06-29 | Abbott Laboratories | Anaphylatoxin-receptor ligands |
| HU225068B1 (en) * | 1989-03-17 | 2006-05-29 | Chiron Corp | Process for producing diagnostics and vaccine of nanbh |
| AU8228791A (en) * | 1990-06-15 | 1992-01-07 | New York University | Heterohybridomas producing human monoclonal antibodies to hiv-1 |
| US5387671A (en) * | 1990-12-27 | 1995-02-07 | Abbott Laboratories | Hexa- and heptapeptide anaphylatoxin-receptor ligands |
| JP3908271B2 (ja) * | 1993-03-05 | 2007-04-25 | エピミューン，インコーポレイティド | Ｈｌａ−ａ２．１結合ペプチドおよびそれらの使用 |
| DE69534077T2 (de) * | 1994-01-14 | 2005-08-11 | Rath, Matthias, Dr.med. | Verwendung von methoden zur identifizierung von hydrophilen signal-oligopeptiden |
| US5709995A (en) * | 1994-03-17 | 1998-01-20 | The Scripps Research Institute | Hepatitis C virus-derived peptides capable of inducing cytotoxic T lymphocyte responses |
| CA2186873A1 (en) * | 1994-04-01 | 1995-10-12 | Charles J. Hackett | Haptenated peptides and uses thereof |
| DE69617396T2 (de) * | 1995-01-16 | 2002-09-05 | Northern Sydney Area Health Service, St. Leonards | T-Zellen beeinflussende Peptide |
| US5753625A (en) * | 1995-05-12 | 1998-05-19 | Sangstat Medical Corporation | Treatment for inhibiting the progression of autoimmune disease |
-
1996
- 1996-01-16 DE DE69617396T patent/DE69617396T2/de not_active Expired - Lifetime
- 1996-01-16 US US08/875,013 patent/US6057294A/en not_active Expired - Fee Related
- 1996-01-16 CA CA002210812A patent/CA2210812C/en not_active Expired - Fee Related
- 1996-01-16 EP EP96900472A patent/EP0804469B1/en not_active Expired - Lifetime
- 1996-01-16 WO PCT/AU1996/000018 patent/WO1996022306A1/en not_active Ceased
- 1996-01-16 JP JP52191796A patent/JP3665342B2/ja not_active Expired - Fee Related
- 1996-01-16 ES ES96900472T patent/ES2168456T3/es not_active Expired - Lifetime
- 1996-01-16 AU AU44272/96A patent/AU694602B2/en not_active Ceased
-
2005
- 2005-02-10 JP JP2005034053A patent/JP2005145985A/ja active Pending
-
2006
- 2006-01-10 JP JP2006002633A patent/JP4522367B2/ja not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPWO2020209285A5 (enExample) | ||
| JP2012525844A5 (enExample) | ||
| MX2007013031A (es) | Agentes terapeuticos de peptidos de toxina. | |
| JP2010519252A5 (enExample) | ||
| JP2013537907A5 (enExample) | ||
| JP2020002154A5 (enExample) | ||
| JP2008529500A5 (enExample) | ||
| JP2011502964A5 (enExample) | ||
| JP2008541759A5 (enExample) | ||
| JP2013507439A5 (enExample) | ||
| JP2006506942A5 (enExample) | ||
| JP2017160222A5 (enExample) | ||
| TW200833840A (en) | Toxin peptide therapeutic agents | |
| JP2009537143A5 (enExample) | ||
| JP2018515101A5 (enExample) | ||
| JP2011528332A5 (enExample) | ||
| MX2013011674A (es) | Derivados de peptido 1 tipo glucagon (glp-1) doblemente acilados. | |
| JP2011511753A5 (enExample) | ||
| JP2005516885A5 (enExample) | ||
| JP2014527040A5 (enExample) | ||
| JP2012505657A5 (enExample) | ||
| JP2014532722A5 (enExample) | ||
| JP2015526391A5 (enExample) | ||
| JP2010513327A5 (enExample) | ||
| JP2009537563A5 (enExample) |